Neurocrine Biosciences Presents Phase III Data Analysis Demonstrating that Opicapone Added to Levodopa Resulted in a Significant and Sustained Increase in ON Time without Troublesome Dyskinesia in Parkinson’s Disease Patients – BioSpace

Neurocrine Biosciences Presents Phase III Data Analysis Demonstrating that Opicapone Added to Levodopa Resulted in a Significant and Sustained Increase in ON Time without Troublesome Dyskinesia in Parkinson’s Disease Patients – BioSpace
Neurocrine Biosciences Presents Phase III Data Analysis Demonstrating that Opicapone Added to Levodopa Resulted in a Significant and Sustained Increase in ON Time without Troublesome Dyskinesia in Parkinson's Disease Patients  BioSpacePublished: May 05, 2019. More than 60% of Patients Treated with Once-Daily Opicapone 50 mg Experienced an Increase in Total ON Time of One Hour or ... read more
Source: Google NewsPublished on 2019-05-06